TOPAZ

TOPAZ: A Randomized, Placebo-controlled Trial of Zoledronic Acid for Prevention of Fractures in Patients with Parkinson’s Disease

The purpose of this study is to evaluate if a drug called Zoledronic Acid will reduce the risk of bone fractures among people with Parkinson’s disease. The study drug is administered in your home, by a clinical nurse, as a one-time infusion under the skin.

Key Criteria:

• Are 60 years or older
• Have Parkinson’s Disease or parkinsonism
• Have not had a hip fracture
• Are not taking a medication for osteoporosis

For more information, contact Hannah Babcock at 617-667-9890 or hbabcock@bidmc.harvard.edu